Without the right patent strategy, drug developers risk losing investors and sacrificing commercial potential.

On this weeks episode of the Business of Biotech, Independent Board Director and five-time public company CFO Alan Shaw returns to the show for an update on current biotech financing and the ...

On this weeks episode of the Business of Biotech, David Craig, Cofounder, President, and CEO at Sarcomatrix, explains why the old biotech playbook breaks down in today’s funding environment and what ...

Deciding whether a drug candidate should be developed as part of a combination or not should hinge on available evidence and ...

On this week's episode of the Business of Biotech, Olivier Litzka, Partner at Andera Partners, talks about what it really takes for biotech companies to attract capital, stay focused, and survive the ...

Spinning off a $4 billion biopharma business is no easy task. Integrated functions need to be separated, governance boards created, leadership teams assembled, and corporate headquarters established.

Speed alone no longer guarantees success; here’s what matters most in today’s launch environment. In today’s launch environment, order of entry (OOE) isn’t destiny. Many brands still anchor strategy ...

Bouncing around the San Diego Convention Center’s 2.6 million square feet for four days is its own kind of flustery exercise, but in the age of Zoom it’s a more-than-welcome excursion. It’s hard to ...

Amid recent and proposed sweeping cuts to federal research funding, ranging from suspended federal funding to universities and research facilities to updated policy by the NIH (NIH) to reduce indirect ...

In pharma, an oncology drug approval is a significant milestone. I have spent enough time in this space to know that it is also the moment where a different, less visible problem begins. The community ...

Life sciences startups have long felt the gravitational pull of Boston and San Francisco when looking to raise capital, expand, and recruit talent. These two coastal regions, with an established ...

For Boehringer Ingelheim’s (BI) first foray into biosimilars, the company went straight to the top, developing an interchangeable biosimilar for AbbVie’s Humira, one of the best-selling pharmaceutical ...